CNTNAP1 and in situ carcinoma: Serum samples taken pre and post-treatment, as well as first treatment session eluates from the IA cohort (20 CIDP, 20 GBS and 20 MS/CIS patients), were tested by both cell-based assay (CBA) and ELISA for antibodies to nodal (neurofascin-186) and paranodal (neurofascin-155, contactin-1 and Caspr) cell adhesion molecules.